VBI VACCINES INC/BC
VBIV evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VBIV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
vbi-1501 (Phase 1/Phase 2)
Next Catalyst
—
Financial data as of Mar 31, 2024.
Tracking 5 pipeline candidates · 3 clinical trials for VBI VACCINES INC/BC.
Run VBI VACCINES INC/BC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available VBI VACCINES INC/BC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
OCF -$12M · Net income -$18M
Lead: Phase 1/Phase 2
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Frequently asked questions
What is VBI VACCINES INC/BC's lead drug candidate?
VBI VACCINES INC/BC's most advanced tracked candidate is vbi-1501 (Phase 1/Phase 2) for Cytomegalovirus (CMV).
Who is the CEO of VBI VACCINES INC/BC?
Jeffrey R. Baxter is the chief executive officer of VBI VACCINES INC/BC (VBIV).
What therapeutic areas does VBI VACCINES INC/BC focus on?
VBI VACCINES INC/BC develops therapies across Oncology, Immunology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.